Echocardiographic assessment and clinical management of tricuspid regurgitation

被引：9
作者：
Bhave N.M. [1 ,2 ,3 ]
Ward R.P. [1 ,2 ]
机构：
[1] Non-Invasive Imaging Laboratories, Department of Medicine, University of Chicago, Chicago, IL
[2] University of Chicago Medical Center, MC6080, Chicago, IL 60637
[3] Section of Cardiology, University of Chicago Medical Center, MC6080, Chicago, IL 60637
来源：
Current Cardiology Reports | 2011年 / 13卷 / 3期
关键词：
3D echocardiography; Doppler echocardiography; Echocardiography; Tricuspid regurgitation; Tricuspid valve;
D O I：
10.1007/s11886-011-0180-7
中图分类号：
学科分类号：
摘要：
The evaluation and management of tricuspid regurgitation (TR) are often challenging. Significant TR is an independent predictor of reduced event-free and overall survival. Therefore, an evidence-based approach to the diagnosis and treatment of TR is of critical importance. TR can be classified into two basic categories: primary and secondary TR. The former refers to conditions in which the primary pathophysiologic process affects the valve itself, whereas the latter is much more common and occurs due to tricuspid annular dilatation, right heart failure, and/or pulmonary hypertension. Two- and three-dimensional echocardiography allow for a comprehensive assessment of TR severity and mechanisms. In patients with fixed pulmonary hypertension and right ventricular dysfunction, medical management of TR is generally preferable. In patients undergoing mitral valve surgery, tricuspid annular dilatation should trigger prophylactic tricuspid valve repair, regardless of the degree of TR. Future efforts in TR management will include development of percutaneous repair procedures. © 2011 Springer Science+Business Media, LLC.
引用
收藏
页码：258 / 264
页数：6
相关论文
共 48 条
[21]  
Bonow R.O., Carabello B.A., Chatterjee K., Et al., ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: Executive summary, Circulation, 114, pp. 450-527, (2006)
[22]  
Mangoni A.A., DiSalvo T.G., Vlahakes G.J., Polanczyk C.A., Fifer M.A., Outcome following isolated tricuspid valve replacement, European Journal of Cardio-thoracic Surgery, 19, 1, pp. 68-73, (2001)
[23]  
Haddad F., Doyle R., Murphy D.J., Hunt S.A., Right ventricular function in cardiovascular disease, part II: Pathophysiology, clinical importance, and management of right ventricular failure, Circulation, 117, pp. 1717-1731, (2008)
[24]  
Haddad F., Hunt S.A., Rosenthal D.N., Murphy D.J., Right ventricular function in cardiovascular disease, part I: Anatomy, physiology, aging, and functional assessment of the right ventricle, Circulation, 117, pp. 1436-1448, (2008)
[25]  
Morrow A.G., Oldham N., Elkins R.C., Braunwald E., Prosthetic replacement of the mitral valve: Preoperative and postoperative assessment in 100 patients, Circulation, 35, pp. 962-979, (1967)
[26]  
Sagie A., Freitas N., Chen M.H., Marshall J.E., Weyman A.K., Levine R.A., Echocardiographic assessment of mitral stenosis and its associated valvular lesions in 205 patients and lack of association with mitral valve prolapse, Journal of the American Society of Echocardiography, 10, 2, pp. 141-148, (1997)
[27]  
Sagie A., Schwammenthal E., Newell J.B., Harrell L., Joziatis T.B., Weyman A.E., Levine R.A., Palacios I.F., Significant tricuspid regurgitation is a marker for adverse outcome in patients undergoing percutaneous balloon mitral valvuloplasty, Journal of the American College of Cardiology, 24, 3, pp. 696-702, (1994)
[28]  
Dreyfus G.D., Corbi P.J., Chan K.M., Bahrami T., Secondary tricuspid regurgitation or dilatation: Which should be the criteria for surgical repair?, Ann Thorac Surg, 79, pp. 127-132, (2005)
[29]  
Shiran A., Sagie A., Tricuspid regurgitation in mitral valve disease: Incidence, prognostic implications, mechanism, and management, J Am Coll Cardiol, 53, pp. 401-408, (2009)
[30]  
Xiao X.J., Huang H.L., Zhang J.F., Et al., Surgical treatment of late tricuspid regurgitation after left cardiac valve replacement, Heart Lung Circ, 13, pp. 65-69, (2004)
12345